SBIR/STTR Research Award
Vagus Nerve Stimulation Treatment for Asthmatic Bronchoconstriction
Award amount
$149,187Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ROSELLINI SCIENTIFIC, LLC
- Proposal award date
- 2017-02-01
- Contract end date
- 2018-01-31
- UEI
- Not reported
- Solicitation number
- PA15-269
- Topic code
- NHLBI
Research abstract
Project Summary
The Specific Aim of this proposal is to test the feasibility of using vagus nerve stimulation VNS for
treating asthma related airway constriction that is refractory to current treatments There are approximately
million people with asthma in the US About percent of these asthma sufferers experience early and late
phase severe asthmatic bronchoconstriction that is refractory to current medication These patients account for
more than half of health related asthma costs and the majority of its mortality This patient population accounts
for emergency department visits per day hospitalizations per day and more than deaths
annually There is currently no treatment for people who suffer from uncontrolled asthma
Other percutaneous devices have proven effective for blocking the early phase of asthma attacks that
are refractory to current therapy in an ED setting but there is currently no effective VNS device for outside of
the ED setting In addition the efficacy of their device for blocking the later phase of the asthma response is
unknown The late phase occurs in of individuals and may account for extended stand and returns to the
ED Our goal is to provide patients with VNS for on demand treatment of both the early and late asthma
responses in order to drastically improve quality of life prevent death and to obviate the need for visiting the
ED However before evaluating our method in humans we must first determine if VNS is effective for halting
both the early and the late phase of asthma In this Phase I study we will achieve our Specific Aim by
evaluating the efficacy of VNS for blocking both early and late asthma responses in an ovalbumin OVA
sensitized guinea pig model of asthma
Guinea pigs are anesthetized with urethane g kg i p Heart rate and blood pressure are measured
via a carotid artery cannula Both jugular veins are also cannulated for administration of drugs The left vagus
nerve will be isolated and immersed in a pool of mineral oil and bipolar cuff electrode will be placed around the
left cervical vagus Animalandapos s body temperature will be maintained at C using a heating blanket Animals are
paralyzed with succinylcholine ml kg min i v and ventilated tidal volume ml g body weight at
breaths per minute via a tracheal cannula using a constant volume pump Harvard Apparatus Co South
Natick MA Bronchoconstriction measured as an increase in pulmonary inflation pressure Ppi via a
pressure transducer on a sidearm of the tracheal cannula will be measured at stated time intervals after
ovalbumin inhalation
Test of Feasibility We must observe mean reduction of max respiratory system resistance
when OVA is combined with VNS in comparison to sham VNS This value was chosen because it is both
directly related to previously demonstrated pulmonary pressure change in guinea pigs and predictive of later
clinically meaningful responses in humans Project Narrative
This is a proposal to develop an on demand treatment for both immediate and long lasting symptoms of
asthma using vagus nerve stimulation There are million Americans with asthma and approximately do
not respond to current methods of treatment The proposed therapy seeks to mitigate debilitating symptoms
and restore quality of life to patients suffering from uncontrolled asthma
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications